BR112021022778A2 - Compostos e métodos para o tratamento de covid-19 - Google Patents

Compostos e métodos para o tratamento de covid-19

Info

Publication number
BR112021022778A2
BR112021022778A2 BR112021022778A BR112021022778A BR112021022778A2 BR 112021022778 A2 BR112021022778 A2 BR 112021022778A2 BR 112021022778 A BR112021022778 A BR 112021022778A BR 112021022778 A BR112021022778 A BR 112021022778A BR 112021022778 A2 BR112021022778 A2 BR 112021022778A2
Authority
BR
Brazil
Prior art keywords
compounds
methods
covid
treatment
cov
Prior art date
Application number
BR112021022778A
Other languages
English (en)
Inventor
David Ticehurst Martyn
John Thiel Andrew
Bezawada Padmavani
Louise Hawking Emma
Bryce Tuttle Jamison
Louis Hoffman Robert
JAINI Rohit
Steven Kania Robert
Kulkarni Samir
Richard Lillis Jonathan
Luthra Suman
Nathan O'brien Laramy Matthew
Rhys Owen Dafydd
Dimitrova Pencheva Klimentina
Youngjin Pettersson Martin
Mahadeo Rane Anil
Forrest Sammons Matthew
Paul Sullivan Bradley
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR112021022778A2 publication Critical patent/BR112021022778A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

COMPOSTOS E MÉTODOS PARA O TRATAMENTO DE COVID-19. A presente invenção refere-se aos compostos de fórmula I em que R1, R2 e ----- são como aqui definidos, composições farmacêuticas compreendendo os compostos e métodos de tratamento de COVID-19 em um paciente através da administração de quantidades terapeuticamente eficazes dos compostos, e métodos de inibição ou prevenção da replicação de SARS-CoV-2 com os compostos.
BR112021022778A 2020-04-05 2021-04-01 Compostos e métodos para o tratamento de covid-19 BR112021022778A2 (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202063005407P 2020-04-05 2020-04-05
US202063038454P 2020-06-12 2020-06-12
US202063061628P 2020-08-05 2020-08-05
US202063065658P 2020-08-14 2020-08-14
US202063073145P 2020-09-01 2020-09-01
US202063114289P 2020-11-16 2020-11-16
US202163163635P 2021-03-19 2021-03-19
PCT/IB2021/052741 WO2021205298A1 (en) 2020-04-05 2021-04-01 Compounds and methods for the treatment of covid-19

Publications (1)

Publication Number Publication Date
BR112021022778A2 true BR112021022778A2 (pt) 2022-11-22

Family

ID=75478095

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022778A BR112021022778A2 (pt) 2020-04-05 2021-04-01 Compostos e métodos para o tratamento de covid-19

Country Status (18)

Country Link
US (1) US11926642B2 (pt)
EP (1) EP3953361A1 (pt)
JP (1) JP2023519035A (pt)
KR (1) KR20210151949A (pt)
CN (1) CN114641485A (pt)
AU (1) AU2021253796B2 (pt)
BR (1) BR112021022778A2 (pt)
CA (1) CA3140164A1 (pt)
CO (1) CO2021015318A2 (pt)
CR (1) CR20210563A (pt)
EC (1) ECSP21080535A (pt)
IL (1) IL288061A (pt)
MX (1) MX2021013934A (pt)
PE (1) PE20220765A1 (pt)
TW (1) TWI807291B (pt)
UY (1) UY39149A (pt)
WO (1) WO2021205298A1 (pt)
ZA (1) ZA202109010B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11124497B1 (en) 2020-04-17 2021-09-21 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
US11174231B1 (en) 2020-06-09 2021-11-16 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
US11351149B2 (en) * 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
US20220204476A1 (en) * 2020-12-21 2022-06-30 The Governors Of The University Of Alberta Rna virus inhibitor compounds and uses thereof
AU2022210132A1 (en) * 2021-01-20 2023-08-31 National University Corporation Hokkaido University Anti-viral agent
CN115073431B (zh) 2021-04-14 2023-09-05 盐野义制药株式会社 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物
WO2022266363A1 (en) * 2021-06-16 2022-12-22 The Scripps Research Institute Protease inhibitors for the treatment of coronavirus infections
TW202320793A (zh) 2021-09-28 2023-06-01 日商塩野義製藥股份有限公司 含有三嗪衍生物之醫藥組合物
EP4289432A1 (en) 2021-11-24 2023-12-13 Shionogi & Co., Ltd Preparation for oral administration containing triazine derivative
WO2023095860A1 (ja) * 2021-11-26 2023-06-01 塩野義製薬株式会社 ３ｃｌプロテアーゼ阻害剤及びｃｏｖｉｄ－１９治療用薬剤を組み合わせることを特徴とするｃｏｖｉｄ－１９治療用医薬
KR20230140401A (ko) * 2022-03-25 2023-10-06 주식회사 미토이뮨테라퓨틱스 항바이러스용 약학적 조성물 및 이의 용도
WO2023196412A1 (en) * 2022-04-06 2023-10-12 Nobias Therapeutics, Inc. Liquid formulations comprising mitogen-activated protein kinase kinase (mek) inhibitors and methods using same
CN114773405B (zh) * 2022-06-21 2022-09-23 和鼎（南京）医药技术有限公司 一种莫那比拉韦的制备方法
CN115054593B (zh) * 2022-07-15 2023-02-03 深圳市人民医院 防治新型冠状病毒肺炎或检测新冠病毒及突变株的药物及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513881A (ja) 2003-11-20 2007-05-31 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｘｉ因子の治療学的使用
WO2005113580A1 (en) 2004-05-21 2005-12-01 Pfizer Inc. Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
WO2006061714A2 (en) 2004-12-09 2006-06-15 Pfizer Inc. Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
MX2011013824A (es) 2009-07-07 2012-01-30 Boehringer Ingelheim Int Composicion farmaceutica para un inhibidor de proteasa del virus de la hepatitis c.
DK3077397T3 (da) * 2013-12-06 2019-12-16 Vertex Pharma 2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf
TW201623265A (zh) 2014-05-09 2016-07-01 奇尼塔公司 抗病毒化合物、醫藥組合物及其使用方法
WO2018085476A1 (en) 2016-11-02 2018-05-11 Centrexion Therapeutics Corporation Stable aqueous capsaicin injectable formulations and medical uses thereof
US10316021B2 (en) * 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands

Also Published As

Publication number Publication date
IL288061A (en) 2022-01-01
US20220017548A1 (en) 2022-01-20
CR20210563A (es) 2022-01-24
TWI807291B (zh) 2023-07-01
KR20210151949A (ko) 2021-12-14
US11926642B2 (en) 2024-03-12
AU2021253796A1 (en) 2021-12-09
CN114641485A (zh) 2022-06-17
CA3140164A1 (en) 2021-10-14
CO2021015318A2 (es) 2021-11-19
TW202202148A (zh) 2022-01-16
PE20220765A1 (es) 2022-05-16
EP3953361A1 (en) 2022-02-16
UY39149A (es) 2021-10-29
ECSP21080535A (es) 2022-03-31
WO2021205298A1 (en) 2021-10-14
JP2023519035A (ja) 2023-05-10
MX2021013934A (es) 2021-12-15
AU2021253796B2 (en) 2023-06-01
ZA202109010B (en) 2023-09-27

Similar Documents

Publication Publication Date Title
BR112021022778A2 (pt) Compostos e métodos para o tratamento de covid-19
BR112021022419A2 (pt) Compostos antivirais contendo nitrila
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
BR112018067930A8 (pt) Composto, sal de ácido trifluoroacético, composição farmacêutica, método para tratamento de uma infecção bacteriana, e, uso de um composto.
BRPI0807749B8 (pt) composto, composição farmacêutica, e, método para a prevenção, tratamento ou melhora de doenças ou condições dérmicas, ou distúrbios de ferida cutânea agudos ou crônicos
BR112020006381A8 (pt) Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
BR112012006010A2 (pt) composto de glicina
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
BR112015003729A2 (pt) composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
BR112022024597A2 (pt) Compostos de 4-oxo-3,4-di-hidroquinazolinona para o tratamento de doenças e distúrbios associados com braf
BR112014017985A8 (pt) Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112023002573A2 (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de infecção viral e distúrbio respiratório e método de inibição de protease viral
BR112022014968A2 (pt) Composto, composição farmacêutica e métodos de inibição do nível de brd9 em uma célula, de inibição da atividade de brd9 em uma célula, de tratamento de um distúrbio, de tratamento de um câncer em um sujeito em necessidade e de tratamento de infecção em um sujeito em necessidade
BR112019000614A2 (pt) derivados de quinazolinona inovadores de inibição de pi3k e composição farmacêutica contendo os mesmos
BR112021026820A2 (pt) Inibidores heterocíclicos de monoacilglicerol lipase (magl)
BR112022022599A2 (pt) Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma
BR112022021957A2 (pt) Imidazopirimidinas como moduladores de il -17
BR112023017367A2 (pt) Composições e métodos para inibição de ceto-hexoquinase (khk)
BR112022025946A2 (pt) Composto, composição farmacêutica e método de tratamento de uma doença
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan
BR112023016958A2 (pt) Compostos para uso no tratamento de uma infecção por vírus envelopado
BR112023017040A2 (pt) Derivados de indolina como inibidores de ddr1 e ddr2

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: PFIZER INC. (US)

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing